SecBot SecBot

OTLK

Outlook Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001649989 Biotech & Drug Discovery
$0.3960 −0.02 (−4.12%)
Nov 16 4:00 PM ET · prev $0.4130
Market cap
$107.1M
Micro cap
Consensus
Buy
70% Buy or better · 10 analysts
Median target
$4.00
+910% · range $1.60–10.50
1 year
−77.6%
from $1.77 · Nov 17
30 days
−19.7%
from $0.4930
52-week range
$0.1980–2.47
−84% from high · low Mar 24
Avg volume 20D
3.10M
shares / day
Short interest
35.55M
≈14.6% of shares · +9.1%
Days to cover
10.1
at average volume
Insider net
+$7.9M
7 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
28
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    7 insiders bought $7.9M at an average $0.6696. No open-market sales. Price is 41% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 13 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    7 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.080 → −$0.075 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +9.1% to 35.55M shares. 10.1 days to cover, ≈14.6% of shares.

  • TrendDOWNTREND

    29% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED8,976,833$5.2M
MARSHALL WACE, LLPDOUBLED8,023,703$4.6M
UBS Group AGDOUBLED3,343,234$1.9M
GEODE CAPITAL MANAGEMENT, LLCADD1,716,408$984.7K
VANGUARD FIDUCIARY TRUST COADD1,067,919$613.0K
CITIGROUP INCDOUBLED221,657$127.1K
JANE STREET GROUP, LLCNEAR_EXIT158,648$91.0K
NewEdge Advisors, LLCDOUBLED60,669$34.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 70% rate it Buy or better
Strong Buy2Buy5Hold3Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +910%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 11, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Aug 14, 2026BTIG
REITERATE
REITERATEBuy
Jul 27, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINNeutral
Jul 27, 2026BTIG
UPGRADE
UPGRADEBuy
Jun 11, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$7.9M
bought · 7 insiders
$0
sold · 0 insiders
−40.9%
vs their $0.6696 cost
DateInsiderTypeValue
Sep 1, 2026
Lundquist Kevin Michael
Chief Financial Officer
Sep 1, 2026
AWARD500,000 sh
Aug 14, 2026
KENYON LAWRENCE A
Chief Financial Officer
Aug 14, 2026
BUY101,010 sh
Aug 14, 2026
KENYON LAWRENCE A
Chief Financial Officer
Aug 14, 2026
BUY101,010 sh
Aug 14, 2026
Jahr Robert Charles
Chief Executive Officer
Aug 14, 2026
BUY151,515 sh
Aug 14, 2026
Jahr Robert Charles
Chief Executive Officer
Aug 14, 2026
BUY151,515 sh
Aug 12, 2026
Sukhtian Ghiath M.
Director
Aug 12, 2026
BUY$2.5M
Aug 12, 2026
Sukhtian Ghiath M.
Director
Aug 12, 2026
BUY2,525,252 sh
Jul 29, 2026
Sukhtian Faisal Ghiath
Director
Jul 29, 2026
BUY$100.0K

Earnings setup

Estimates
−$0.07
EPS estimate, this quarter
+6%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.07-$0.08–-$0.07-36.4%$2.2M
Next Q-$0.05-$0.08–-$0.01+6.7%$5.3M
Current FY-$0.43-$0.45–-$0.42+11.8%$682.7K
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
35,546,027
shares short
+9.1%
vs prior settlement
10.1
days to cover
≈14.6%
of shares outstanding
Trading halts
Jul 24, 2026Volatility PauseResumed
Jul 24, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 30, 2026 Short interest report
Short Interest: OTLK up 9% to 35.5M shares
Settlement 2026-10-30 | Days to cover: 10.10 | ≈14.60% of shares outstanding (est.)
Oct 13, 2026 SEC
Empery Asset Management, LP filed a Schedule 13G disclosing a passive 8.73% stake in Outlook Therapeutics, Inc…
SC 13G · Impact 4/10
Oct 6, 2026 Press
Outlook Therapeutics participated in a Virtual Investor segment featuring its new CFO Kevin Lundquist, who discussed…
Impact 3/10
Sep 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC · DOUBLED
8,976,833 shares ($5.2M)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · DOUBLED
8,023,703 shares ($4.6M)
Sep 18, 2026 SEC
Outlook Therapeutics announced the U.S. wholesale acquisition cost (WAC) for LYTENAVA at $485 per vial on September…
8-K · Impact 3/10
Sep 1, 2026 Insider
Lundquist Kevin Michael was granted 500,000 shares
Chief Financial Officer
Aug 14, 2026 SEC
Outlook Therapeutics reported Q3 FY2026 results with net loss of $20.3M ($0.15 GAAP EPS, $0.09 adjusted) and revenue…
8-K · Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 30, 2026
Short interest
Short Interest: OTLK up 9% to 35.5M shares
Settlement 2026-10-30 | Days to cover: 10.10 | ≈14.60% of shares outstanding (est.)
Oct 6, 2026
FDA
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of…
Oct 2, 2026
Listing
Listing Status: OTLK, Deficient (was Normal)
Outlook Therapeutics, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Oct 1, 2026
Press release
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement
Sep 11, 2026
Press release
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

SecBot reports

28 filings · 9 press releases · 6 bullish · 11 bearish · 2 mixed · 9 neutral
All OTLK filing & press-release reports (37)